See more : Metrospaces, Inc. (MSPC) Income Statement Analysis – Financial Results
Complete financial analysis of CellSeed Inc. (7776.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CellSeed Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- N G Industries LTD (NGIND.BO) Income Statement Analysis – Financial Results
- Tuktu Resources Ltd. (JAMGF) Income Statement Analysis – Financial Results
- Investor AB (publ) (IVSBF) Income Statement Analysis – Financial Results
- Warburg Pincus Capital Corporation I-B (WPCB) Income Statement Analysis – Financial Results
- Dongkuk Structures & Construction Company Limited (100130.KQ) Income Statement Analysis – Financial Results
CellSeed Inc. (7776.T)
About CellSeed Inc.
CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 190.13M | 126.43M | 161.67M | 199.47M | 275.82M |
| Cost of Revenue | 82.98M | 65.41M | 77.64M | 61.28M | 59.20M |
| Gross Profit | 107.16M | 61.02M | 84.04M | 138.19M | 216.63M |
| Gross Profit Ratio | 56.36% | 48.26% | 51.98% | 69.28% | 78.54% |
| Research & Development | 456.41M | 444.76M | 541.24M | 438.84M | 591.36M |
| General & Administrative | 0.00 | 0.00 | 58.00M | 63.00M | 62.00M |
| Selling & Marketing | 0.00 | 0.00 | 329.00M | 339.00M | 361.00M |
| SG&A | 348.52M | 359.48M | 387.00M | 402.00M | 451.24M |
| Other Expenses | 0.00 | 256.00K | 193.00K | 212.00K | 0.00 |
| Operating Expenses | 804.93M | 804.23M | 948.15M | 857.71M | 1.04B |
| Cost & Expenses | 887.91M | 869.64M | 1.03B | 918.99M | 1.10B |
| Interest Income | 13.00K | 22.00K | 41.00K | 58.00K | 0.00 |
| Interest Expense | 1.13M | 835.00K | 911.00K | 152.00K | 0.00 |
| Depreciation & Amortization | 7.94M | 7.89M | 2.49M | 9.78M | 5.50M |
| EBITDA | -836.52M | -750.00M | -905.68M | -770.13M | -776.89M |
| EBITDA Ratio | -439.96% | -589.71% | -533.43% | -368.37% | -297.46% |
| Operating Income | -697.78M | -743.22M | -864.11M | -719.52M | -825.97M |
| Operating Income Ratio | -366.99% | -587.86% | -534.48% | -360.72% | -299.46% |
| Total Other Income/Expenses | -147.81M | -15.52M | -44.97M | -60.54M | -2.57M |
| Income Before Tax | -845.58M | -758.73M | -909.07M | -780.06M | -782.57M |
| Income Before Tax Ratio | -444.73% | -600.13% | -562.29% | -391.07% | -283.72% |
| Income Tax Expense | 950.00K | 950.00K | 3.80M | 3.80M | -172.00K |
| Net Income | -846.53M | -759.68M | -912.87M | -783.86M | -782.40M |
| Net Income Ratio | -445.23% | -600.88% | -564.64% | -392.98% | -283.66% |
| EPS | -29.43 | -36.31 | -53.08 | -55.31 | -66.60 |
| EPS Diluted | -29.43 | -36.31 | -53.08 | -55.31 | -66.60 |
| Weighted Avg Shares Out | 28.76M | 20.92M | 17.20M | 14.17M | 11.75M |
| Weighted Avg Shares Out (Dil) | 28.76M | 20.92M | 17.20M | 14.17M | 11.75M |
Source: https://incomestatements.info
Category: Stock Reports